| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Not applicable. 19-Noretiocholanolone is a metabolite of nandrolone, an anabolic androgenic steroid (AAS). As a metabolite, it does not have significant androgen receptor (AR) binding activity or direct pharmacological effects. The parent compound, nandrolone (19-nortestosterone), is an AR agonist that promotes protein synthesis, muscle growth, and development of male secondary sex characteristics. 19-Noretiocholanolone is an inactive metabolite used as a urinary biomarker to detect nandrolone exposure. |
|---|---|
| ln Vitro |
19-Noretiocholanolone is an anabolic androgenic steroid metabolite of nandrolone. It is an analytical reference standard used for the detection of nandrolone abuse in sports. Nandrolone is one of the synthetic anabolic steroids banned in sports and has been a popular substance abused by athletes. 19-Noretiocholanolone is a primary urinary metabolite of nandrolone, along with 19-norandrosterone. These metabolites can be endogenously produced in non-treated humans under certain conditions, complicating doping control interpretations.
|
| ln Vivo |
19-Noretiocholanolone is not a drug and is not administered in vivo for therapeutic purposes. It is a metabolite detected in urine following nandrolone administration. In vivo, nandrolone is metabolized to 19-noretiocholanolone and 19-norandrosterone, which are excreted in urine. The ratio of these metabolites and their concentrations are used in anti-doping laboratories to distinguish between endogenous production and exogenous administration. Recent studies have shown that 19-NE can be endogenously produced in non-treated humans.
|
| Enzyme Assay |
Not applicable. 19-Noretiocholanolone is an analytical reference standard for LC-MS/MS and GC-MS analysis. A typical protocol for detection in urine: Urine sample (2-5 mL) is treated with beta-glucuronidase (50 uL, 1000 U/mL) in acetate buffer (pH 5.2) at 55degC for 60 minutes to hydrolyze conjugates. After enzymatic hydrolysis, the sample is subjected to liquid-liquid extraction or solid-phase extraction. The extract is derivatized (e.g., with MSTFA or PFPA) to form trimethylsilyl (TMS) or pentafluoropropionyl (PFP) derivatives. The derivatized sample is analyzed by GC-MS in SIM mode or by LC-MS/MS with MRM transitions (e.g., m/z 405→195 for 19-NE-TMS). Quantification is performed using deuterated internal standards (19-NE-d3).
|
| Cell Assay |
Not applicable. 19-Noretiocholanolone is an analytical standard and is not used in cell-based assays as a pharmacological agent. For studies of nandrolone metabolism, hepatocytes (primary human or rat hepatocytes) are cultured and treated with nandrolone (1-100 uM) for 24-72 hours. Culture supernatants are collected, and the concentrations of 19-noretiocholanolone and other metabolites are measured by LC-MS/MS to study the metabolic profile and CYP450 isozymes involved.
|
| Animal Protocol |
Not applicable. 19-Noretiocholanolone is not administered directly to animals. For studying nandrolone metabolism, animals (e.g., male rats) are administered nandrolone intramuscularly or subcutaneously (e.g., 10-50 mg/kg). Urine is collected for 24-72 hours post-dosing. The urine is processed (hydrolysis, extraction, derivatization) and analyzed by GC-MS or LC-MS/MS for the presence and quantification of 19-noretiocholanolone and 19-norandrosterone metabolites. This data is used to establish the metabolic profile and detection windows for anti-doping purposes.
|
| ADME/Pharmacokinetics |
Not applicable. 19-Noretiocholanolone is a metabolite and analytical standard, not a drug candidate. The pharmacokinetics of nandrolone are well-characterized: after intramuscular injection, nandrolone is absorbed slowly, with a peak plasma concentration at 1-3 days, a terminal half-life of 4-8 days, and is extensively metabolized in the liver. 19-Noretiocholanolone appears in urine within 24-48 hours and can be detectable for 1-3 weeks or longer depending on the dose.
|
| Toxicity/Toxicokinetics |
19-Noretiocholanolone is an androgenic steroid metabolite and is not itself a therapeutic drug. It is used as a biomarker for nandrolone abuse. Nandrolone and other AAS have significant toxicities including hepatotoxicity, cardiovascular effects (dyslipidemia, hypertension), endocrine suppression (hypogonadism, infertility), psychiatric effects (aggression, mood disorders), and androgenic side effects (acne, hirsutism, alopecia). For research use as an analytical standard, standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
19-Noretiocholanolone (CAS: 33036-33-8) has molecular formula C18H28O2 and molecular weight 276.41. IUPAC name: (3alpha,5beta)-3-hydroxyestr-13-en-17-one. Also known as 19-NE, 19-norandrosterone, and 3alpha-hydroxy-5beta-estran-17-one. Appearance: White to off-white crystalline solid. It is an analytical reference standard for nandrolone metabolite detection in doping control and forensic toxicology. For research use only, not for human or veterinary consumption.
|
| Molecular Formula |
C18H28O2
|
|---|---|
| Molecular Weight |
276.41
|
| Exact Mass |
276.209
|
| CAS # |
33036-33-8
|
| PubChem CID |
14009228
|
| Appearance |
Typically exists as solids at room temperature
|
| LogP |
3.569
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
20
|
| Complexity |
418
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
OC1CCC2C3CCC4(C(CCC4C3CCC2C1)=O)C
|
| InChi Key |
UOUIARGWRPHDBX-DHMVHTBWSA-N
|
| InChi Code |
InChI=1S/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h11-16,19H,2-10H2,1H3/t11-,12-,13+,14-,15-,16+,18+/m1/s1
|
| Chemical Name |
(3R,5R,8R,9R,10S,13S,14S)-3-hydroxy-13-methyl-2,3,4,5,6,7,8,9,10,11,12,14,15,16-tetradecahydro-1H-cyclopenta[a]phenanthren-17-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6178 mL | 18.0891 mL | 36.1781 mL | |
| 5 mM | 0.7236 mL | 3.6178 mL | 7.2356 mL | |
| 10 mM | 0.3618 mL | 1.8089 mL | 3.6178 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
